LEADERSHIP

 
Dr. Zarur is Co-Founder, Chairman & CEO of GreenLight Biosciences. Dr. Zarur has been active in early stage life sciences companies for over 20 years, and has actively participated in the creation of over a dozen companies in the healthcare and clean energy sectors. He is also a partner at Kodiak Venture Partners, a venture capital firm specializing in the formation of early stage information and life technology investments. Prior to joining Kodiak Venture Partners, he was founder and CEO of BioProcessors (now part of Agilent Technologies). In addition to BioProcessors, he has led four life science companies from inception to exit. He is also a co-founder and chairman of the board for Lumicell, and chairman of the board for Allegro Diagnostics. Dr. Zarur was named a Young Global Leader of the World Economic Forum in 2005, and he is an Overseer of the Museum of Science in Boston and a Senior Lecturer at MIT Sloan School of Management. Dr. Zarur holds Masters of Science degrees and a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology, and undergraduate degrees from the National University of Mexico. Dr. Zarur is the author of several peer-reviewed articles and holds close to 100 provisional and issued patents.

Dr. Zarur is Co-Founder, Chairman & CEO of GreenLight Biosciences. Dr. Zarur has been active in early stage life sciences companies for over 20 years, and has actively participated in the creation of over a dozen companies in the healthcare and clean energy sectors. He is also a partner at Kodiak Venture Partners, a venture capital firm specializing in the formation of early stage information and life technology investments. Prior to joining Kodiak Venture Partners, he was founder and CEO of BioProcessors (now part of Agilent Technologies). In addition to BioProcessors, he has led four life science companies from inception to exit. He is also a co-founder and chairman of the board for Lumicell, and chairman of the board for Allegro Diagnostics. Dr. Zarur was named a Young Global Leader of the World Economic Forum in 2005, and he is an Overseer of the Museum of Science in Boston and a Senior Lecturer at MIT Sloan School of Management. Dr. Zarur holds Masters of Science degrees and a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology, and undergraduate degrees from the National University of Mexico. Dr. Zarur is the author of several peer-reviewed articles and holds close to 100 provisional and issued patents.

ANDREY J. ZARUR, PH.D

Co-Founder, Chairman, & CEO

Carole Cobb has over 25 years of experience in Biotechnology/ Fermentation-based Commercial Manufacturing, Process Development, Plant Operations and Supply Chain Management. Ms. Cobb was formerly the SVP, Global Supply, for Danisco A/S and Genencor International. During her tenure at Danisco/Genencor, Ms. Cobb successfully led the companies' biotechnology-based manufacturing strategy, growth and implementation, more than doubling the manufacturing infrastructure, including new plant construction and major capital expansions in Asia, South America and Europe, while increasing the output by more than 4X. Ms. Cobb oversaw ten manufacturing plants and 3 major warehouses worldwide. Ms. Cobb holds a M.B.A. in Finance and a B.S. in Chemical Engineering, Biochemistry and Cell and Molecular Biology.

Carole Cobb has over 25 years of experience in Biotechnology/ Fermentation-based Commercial Manufacturing, Process Development, Plant Operations and Supply Chain Management. Ms. Cobb was formerly the SVP, Global Supply, for Danisco A/S and Genencor International. During her tenure at Danisco/Genencor, Ms. Cobb successfully led the companies' biotechnology-based manufacturing strategy, growth and implementation, more than doubling the manufacturing infrastructure, including new plant construction and major capital expansions in Asia, South America and Europe, while increasing the output by more than 4X. Ms. Cobb oversaw ten manufacturing plants and 3 major warehouses worldwide. Ms. Cobb holds a M.B.A. in Finance and a B.S. in Chemical Engineering, Biochemistry and Cell and Molecular Biology.

CAROLE COBB, MBA

Chief Operating Officer

Mrs. Ortega-Valle is a Co-Founder of GreenLight and leads the company’s corporate development efforts, deploying collaboration agreements and taking products to commercialization with strategic partners in the chemical, pharmaceutical, consumer goods, and energy industries. Since the Company’s creation, Mrs. Ortega-Valle has successfully led multi-million collaboration agreements with life science companies from definition to execution. Prior to joining GreenLight, Mrs. Ortega-Valle was entrepreneur in residence at Kodiak Venture Partners where she started GreenLight with Dr. Zarur and Professor James Swartz.   Prior to that, Ms. Ortega-Valle was a senior manager at Accenture France, where she led the business intelligence group in Paris. As general manager of that group she was responsible for growth and business development, strategic partner relations, and large engagements management. Ortega-Valle has nine years of experience in business development and project management in global consulting engagement for companies in USA and Europe. Ortega-Valle holds a Master of Business Administration from Massachusetts Institute of Technology, Sloan Fellows Program at the Sloan School of Management, and a Master of Science in Electrical Engineering from ETSEIB (UPC) Engineering School of Barcelona.

Mrs. Ortega-Valle is a Co-Founder of GreenLight and leads the company’s corporate development efforts, deploying collaboration agreements and taking products to commercialization with strategic partners in the chemical, pharmaceutical, consumer goods, and energy industries. Since the Company’s creation, Mrs. Ortega-Valle has successfully led multi-million collaboration agreements with life science companies from definition to execution. Prior to joining GreenLight, Mrs. Ortega-Valle was entrepreneur in residence at Kodiak Venture Partners where she started GreenLight with Dr. Zarur and Professor James Swartz.   Prior to that, Ms. Ortega-Valle was a senior manager at Accenture France, where she led the business intelligence group in Paris. As general manager of that group she was responsible for growth and business development, strategic partner relations, and large engagements management. Ortega-Valle has nine years of experience in business development and project management in global consulting engagement for companies in USA and Europe. Ortega-Valle holds a Master of Business Administration from Massachusetts Institute of Technology, Sloan Fellows Program at the Sloan School of Management, and a Master of Science in Electrical Engineering from ETSEIB (UPC) Engineering School of Barcelona.

Marta Ortega-Valle, M.Sc., MBA

Co-Founder, Senior Vice President of Corporate Development

Dr. Cunningham is the Director of Platform Research and Development at GreenLight Biosciences, where he leads teams focused on both the fundamental understanding of cell-free systems as well as the development of GreenLight’s cell-free platform. Dr. Cunningham has eight years of industrial biotechnology experience with expertise in cell-free bioprocessing, metabolic engineering, and bacterial physiology. Prior to joining GreenLight, Dr. Cunningham obtained a Doctor of Philosophy degree in Chemical Engineering from Carnegie Mellon University, where his doctoral efforts focused on producing plasmid DNA vaccines in bacterial hosts that were engineered using rational, model-predicted mutational strategies and synthetic biology. While attending Carnegie Mellon, Dr. Cunningham was an NIH Biotechnology Training Grant Fellow and received the Ken Meyer Graduate Research Award for research excellence. Dr. Cunningham also holds a Bachelor of Science degree in Chemical Engineering from the University of Pittsburgh, where he was the recipient of a Professional Promise Award by the American Institute of Chemical Engineers. Dr. Cunningham is an author of peer-reviewed publications in the fields of metabolic engineering, bacteriology, and biotechnology. In addition, he is an inventor on several awarded patents and provisional patents pertaining to cell-free bioprocessing and pathway engineering.

Dr. Cunningham is the Director of Platform Research and Development at GreenLight Biosciences, where he leads teams focused on both the fundamental understanding of cell-free systems as well as the development of GreenLight’s cell-free platform. Dr. Cunningham has eight years of industrial biotechnology experience with expertise in cell-free bioprocessing, metabolic engineering, and bacterial physiology. Prior to joining GreenLight, Dr. Cunningham obtained a Doctor of Philosophy degree in Chemical Engineering from Carnegie Mellon University, where his doctoral efforts focused on producing plasmid DNA vaccines in bacterial hosts that were engineered using rational, model-predicted mutational strategies and synthetic biology. While attending Carnegie Mellon, Dr. Cunningham was an NIH Biotechnology Training Grant Fellow and received the Ken Meyer Graduate Research Award for research excellence. Dr. Cunningham also holds a Bachelor of Science degree in Chemical Engineering from the University of Pittsburgh, where he was the recipient of a Professional Promise Award by the American Institute of Chemical Engineers. Dr. Cunningham is an author of peer-reviewed publications in the fields of metabolic engineering, bacteriology, and biotechnology. In addition, he is an inventor on several awarded patents and provisional patents pertaining to cell-free bioprocessing and pathway engineering.

DREW CUNNINGHAM, Ph.d

Director of Platform R&D

Dr. MacEachran is the Director of Applications R&D for Greenlight’s Cell--Free RNA production platform. In this role, Dr. MacEachran works to to identify novel applications for Greenlight’s technology focusing primarily in agricultural applications. Dr. MacEachran brings over 9 years of experience in the production of biochemicals using fermentation and cell-free technologies in both academic, as a postdoctoral fellow at the Massachusetts Institute of Technology, and industrial settings. He holds a PhD in Microbiology from the Dartmouth Medical School and a BS from Colorado State University.

Dr. MacEachran is the Director of Applications R&D for Greenlight’s Cell--Free RNA production platform. In this role, Dr. MacEachran works to to identify novel applications for Greenlight’s technology focusing primarily in agricultural applications. Dr. MacEachran brings over 9 years of experience in the production of biochemicals using fermentation and cell-free technologies in both academic, as a postdoctoral fellow at the Massachusetts Institute of Technology, and industrial settings. He holds a PhD in Microbiology from the Dartmouth Medical School and a BS from Colorado State University.

DANIEL MACEACHRAN, PH.D

Director of Application R&D

Dr. Skizim is the Manager of Analytical Chemistry at Greenlight Biosciences. His group is responsible for executing a range of analytical assays, providing quantification of key pathway intermediates, analysis of pathway enzyme activities, and characterization of Greenlight's cell-free RNA products. Dr. Skizim brings over 10 years experience in engineering the microbial production of various fuels and chemicals and the parallel characterization of these intermediates and products in complex systems. He holds a Ph.D. in Chemistry from Princeton University, and a B.Sc. in Biochemistry from the University of Virginia.

Dr. Skizim is the Manager of Analytical Chemistry at Greenlight Biosciences. His group is responsible for executing a range of analytical assays, providing quantification of key pathway intermediates, analysis of pathway enzyme activities, and characterization of Greenlight's cell-free RNA products. Dr. Skizim brings over 10 years experience in engineering the microbial production of various fuels and chemicals and the parallel characterization of these intermediates and products in complex systems. He holds a Ph.D. in Chemistry from Princeton University, and a B.Sc. in Biochemistry from the University of Virginia.

NICHOLAS SKIZIM,ph.d

Manager of Analytical Chemistry


BOARD OF DIRECTORS

20151109-132356-39.jpg

ANDREY J. ZARUR, PH.D.

Co-Founder, Chairman, & CEO, GreenLight Biosciences, Inc.

Dr. James Swartz is a Co-Founder of GreenLight Biosciences and a Professor in the Departments of Bioengineering and Chemical Engineering at Stanford University. Prof. Swartz has over twenty years of industrial experience at Eli Lilly and Genentech in the genetic engineering of recombinant organisms, and in the development of large scale processes for recombinant protein production. His research seeks to reproduce and direct complex metabolism in a cell-free environment. Prof Swartz is also a co-founder of Sutro Biopharma, Inc. and of Bullet Biotechnology. He also serves on the Board of Directors for Sutro Biopharma. He is a co-author or inventor for numerous scientific publications and patents related to large scale protein production as well as cell-free protein synthesis. Prof. Swartz holds a Master and Doctorate of Science degree in Chemical Engineering and Biochemical Engineering from the Massachusetts Institute of Technology, and a Bachelor of Science degree in Chemical Engineering from the South Dakota School of Mines.

Dr. James Swartz is a Co-Founder of GreenLight Biosciences and a Professor in the Departments of Bioengineering and Chemical Engineering at Stanford University. Prof. Swartz has over twenty years of industrial experience at Eli Lilly and Genentech in the genetic engineering of recombinant organisms, and in the development of large scale processes for recombinant protein production. His research seeks to reproduce and direct complex metabolism in a cell-free environment. Prof Swartz is also a co-founder of Sutro Biopharma, Inc. and of Bullet Biotechnology. He also serves on the Board of Directors for Sutro Biopharma. He is a co-author or inventor for numerous scientific publications and patents related to large scale protein production as well as cell-free protein synthesis. Prof. Swartz holds a Master and Doctorate of Science degree in Chemical Engineering and Biochemical Engineering from the Massachusetts Institute of Technology, and a Bachelor of Science degree in Chemical Engineering from the South Dakota School of Mines.

Prof. James SwartZ, Ph.D.

Professor of Bioengineering and Chemical Engineering, Stanford University; Co-Founder

Dr. Charles L. Cooney is a Professor of Chemical Engineering and Faculty Director of the Deshpande Center for Technological Innovation at the Massachusetts Institute of Technology. He is an expert in process design and development for biological products and has served as a consultant to multiple biotech and pharmaceutical companies. Prof. Cooney also sits on the boards of Polypore International, and Biocon, Ltd. (India) as well as LS9, Pronutria, and Mitra Biosciences. His research and teaching span many aspects of biochemical engineering and pharmaceutical manufacturing. Prof. Cooney holds a Master of Science degree and Doctor of Philosophy degree in biochemical engineering from the Massachusetts Institute of Technology, and his Bachelor of Science degree in chemical engineering from the University of Pennsylvania.

Dr. Charles L. Cooney is a Professor of Chemical Engineering and Faculty Director of the Deshpande Center for Technological Innovation at the Massachusetts Institute of Technology. He is an expert in process design and development for biological products and has served as a consultant to multiple biotech and pharmaceutical companies. Prof. Cooney also sits on the boards of Polypore International, and Biocon, Ltd. (India) as well as LS9, Pronutria, and Mitra Biosciences. His research and teaching span many aspects of biochemical engineering and pharmaceutical manufacturing. Prof. Cooney holds a Master of Science degree and Doctor of Philosophy degree in biochemical engineering from the Massachusetts Institute of Technology, and his Bachelor of Science degree in chemical engineering from the University of Pennsylvania.

Prof. Charles L. Cooney, Ph.d.

Professor of Chemical Engineering, Massachusetts Institute of Technology 

David Furneaux is the Founder and Managing Partner of Kodiak Venture Partners. Furneaux has over 15 years of venture investing and company building experience. He focuses on a broad range of opportunities in information technology and Internet markets. Furneaux also represents Kodiak on the Boards of Application Security, BTI Systems, Lumicell Diagnostics, and Vette Corp. He is also an observer on the board for Cortina. During his career as an entrepreneur, investor and fund manager, Furneaux has been directly involved in the conception, founding, launching and operations of many high growth companies in the information technology landscape. Selected earlier investments include ALIS (Karl Zeiss), Auroranetics (Cisco), Extreme Packet Devices (PMC-Sierra), Enfora (Novatel), Philsar (IDT), RMI (Netlogic) Skystone (Cisco), Telica (Alcatel/Lucent) and Watchfire (IBM). Furneaux holds a Bachelor of Arts degree from Colorado College, where he was a member of Phi Beta Kappa.

David Furneaux is the Founder and Managing Partner of Kodiak Venture Partners. Furneaux has over 15 years of venture investing and company building experience. He focuses on a broad range of opportunities in information technology and Internet markets. Furneaux also represents Kodiak on the Boards of Application Security, BTI Systems, Lumicell Diagnostics, and Vette Corp. He is also an observer on the board for Cortina. During his career as an entrepreneur, investor and fund manager, Furneaux has been directly involved in the conception, founding, launching and operations of many high growth companies in the information technology landscape. Selected earlier investments include ALIS (Karl Zeiss), Auroranetics (Cisco), Extreme Packet Devices (PMC-Sierra), Enfora (Novatel), Philsar (IDT), RMI (Netlogic) Skystone (Cisco), Telica (Alcatel/Lucent) and Watchfire (IBM). Furneaux holds a Bachelor of Arts degree from Colorado College, where he was a member of Phi Beta Kappa.

David Furneaux

Managing Partner, Kodiak Venture Partners

Gabriel joined Syngenta Ventures in 2013. Prior to this he was a consultant with Wilson Perumal & Company, focused on operations and strategy. Before that, he was a factory manager for the industrial products company Danaher Corp, where he was responsible for ~$100m revenue manufacturing division. Prior to business school, Gabriel worked with early-stage technology start-ups as the Associate Director for the University of Kentucky’s Center for Entrepreneurship. Gabriel has deep agricultural expertise from early career roles in agriculture research and with several nationally-recognized production farms; from working with small farmers in Tanzania with the US Peace Corps; and from spending summers on his family’s sixth generation farm in West Virginia. Gabriel earned an M.B.A. from Harvard Business School. He holds Bachelor's and Master's degrees in Biochemistry from Virginia Tech.

Gabriel joined Syngenta Ventures in 2013. Prior to this he was a consultant with Wilson Perumal & Company, focused on operations and strategy. Before that, he was a factory manager for the industrial products company Danaher Corp, where he was responsible for ~$100m revenue manufacturing division. Prior to business school, Gabriel worked with early-stage technology start-ups as the Associate Director for the University of Kentucky’s Center for Entrepreneurship.

Gabriel has deep agricultural expertise from early career roles in agriculture research and with several nationally-recognized production farms; from working with small farmers in Tanzania with the US Peace Corps; and from spending summers on his family’s sixth generation farm in West Virginia.

Gabriel earned an M.B.A. from Harvard Business School. He holds Bachelor's and Master's degrees in Biochemistry from Virginia Tech.

Gabriel Wilmoth

Investment Director, Syngenta Ventures

Dr. Neil Renninger is an Entrepreneur-in-Residence at Khosla Ventures. Dr. Renninger co-founded Amyris, Inc. in 2003 and served as its Chief Technical Officer from 2008 to 2013. Dr. Renninger also sat on the Board of Directors at Amyris, Inc., from 2003 to 2008, and from 2011 to 2013. He has a cross-disciplinary understanding of both the micro-world of strain engineering and the macro-world of chemical engineering, and has been recognized as one of the world’s top innovators under the age of 35 by Technology Review Magazine. Dr. Renninger holds a Master of Science degree in Environmental Engineering and a Doctor of Philosophy degree in Chemical Engineering from the University of California, Berkeley, and a Bachelor of Science degree in Chemical Engineering from the Massachusetts Institute of Technology.

Dr. Neil Renninger is an Entrepreneur-in-Residence at Khosla Ventures. Dr. Renninger co-founded Amyris, Inc. in 2003 and served as its Chief Technical Officer from 2008 to 2013. Dr. Renninger also sat on the Board of Directors at Amyris, Inc., from 2003 to 2008, and from 2011 to 2013. He has a cross-disciplinary understanding of both the micro-world of strain engineering and the macro-world of chemical engineering, and has been recognized as one of the world’s top innovators under the age of 35 by Technology Review Magazine. Dr. Renninger holds a Master of Science degree in Environmental Engineering and a Doctor of Philosophy degree in Chemical Engineering from the University of California, Berkeley, and a Bachelor of Science degree in Chemical Engineering from the Massachusetts Institute of Technology.

Neil Renninger

CEO, Ripple Foods

Jonathan Fleming is the President and CEO of Q-State Biosciences. Prior to joining Q-State Mr. Fleming had a 30 year venture capital career in starting, financing, and building neuroscience companies dedicated to drug discovery and development. Examples of companies he has been involved in starting and building include: Chairman of Synaptic Pharmaceuticals, which was acquired by Lundbeck; Chairman of Memory Pharmaceuticals, which was acquired by Hoffman La Roche; Chairman of Brain Cells; Chairman of Hypnion Pharmaceuticals which was acquired by Eli Lilly. In addition Mr. Fleming's venture capital firm Oxford Bioscience Partners, of which he was the Managing Partner, was closely involved in the creation of the instrument by Solexa, subsequently sold to Illumina, that is used in high thru put sequencing throughout the world. Mr. Fleming's firm was also deeply involved in the creation of the high content screening market in the pharmaceutical industry by building Cellomics - now part of Thermo Fisher. Mr. Fleming was a lead director of the Board of Cellomics in the years prior to its acquisition. For the past ten years Mr. Fleming has taught the core course on life science strategy at the MIT Sloan School of Business. He is a director of Leerink Partners a highly regarded investment bank specializing in the life sciences as well as several other private life science companies.

Jonathan Fleming is the President and CEO of Q-State Biosciences. Prior to joining Q-State Mr. Fleming had a 30 year venture capital career in starting, financing, and building neuroscience companies dedicated to drug discovery and development. Examples of companies he has been involved in starting and building include: Chairman of Synaptic Pharmaceuticals, which was acquired by Lundbeck; Chairman of Memory Pharmaceuticals, which was acquired by Hoffman La Roche; Chairman of Brain Cells; Chairman of Hypnion Pharmaceuticals which was acquired by Eli Lilly.

In addition Mr. Fleming's venture capital firm Oxford Bioscience Partners, of which he was the Managing Partner, was closely involved in the creation of the instrument by Solexa, subsequently sold to Illumina, that is used in high thru put sequencing throughout the world. Mr. Fleming's firm was also deeply involved in the creation of the high content screening market in the pharmaceutical industry by building Cellomics - now part of Thermo Fisher. Mr. Fleming was a lead director of the Board of Cellomics in the years prior to its acquisition. For the past ten years Mr. Fleming has taught the core course on life science strategy at the MIT Sloan School of Business. He is a director of Leerink Partners a highly regarded investment bank specializing in the life sciences as well as several other private life science companies.

Jonathan J. Fleming, mpa

President and CEO of Q-State Biosciences; Independent Director

Eric O’Brien is Co-Founder and Managing Director of Fall Line Capital, bringing over 18 years of professional investment, financial services and operating experience to the firm. Prior to forming Fall Line with Clay Mitchell in 2011, Eric spent 12 years at Lightspeed Venture Partners, a top tier Silicon Valley venture capital firm with over $3 billion of assets under management.  At Lightspeed, he was a Managing Director responsible for early and growth stage investments in technology and services companies in the U.S. and China. Eric has a track record of identifying and executing effectively against emerging market opportunities. In 2004, he identified a strategic opportunity for Lightspeed to expand its activities to China, where very few U.S. venture capital firms had established themselves at the time. That year, he sourced the firm’s first investment in the region and led the creation of Lightspeed’s overall strategy for China. In 2006, he moved himself and his family to Shanghai for five months to help formally establish Lightspeed’s China office, build the local investment team, and make several of the firm’s initial investments in the region, one of which became the firm’s first successful liquidity event in China. Prior to Lightspeed, Eric was an Associate at InterWest Partners, a Silicon Valley venture capital firm where he focused on communications, internet and consumer investments. He has also worked for and consulted to a number of technology startups, and started his career as an Analyst in the mergers and acquisitions and corporate finance groups at Morgan Stanley in New York and San Francisco. Eric holds an AB degree in Economics magna cum laude from Harvard College and an MBA from the Stanford Graduate School of Business.

Eric O’Brien is Co-Founder and Managing Director of Fall Line Capital, bringing over 18 years of professional investment, financial services and operating experience to the firm. Prior to forming Fall Line with Clay Mitchell in 2011, Eric spent 12 years at Lightspeed Venture Partners, a top tier Silicon Valley venture capital firm with over $3 billion of assets under management.  At Lightspeed, he was a Managing Director responsible for early and growth stage investments in technology and services companies in the U.S. and China.

Eric has a track record of identifying and executing effectively against emerging market opportunities. In 2004, he identified a strategic opportunity for Lightspeed to expand its activities to China, where very few U.S. venture capital firms had established themselves at the time. That year, he sourced the firm’s first investment in the region and led the creation of Lightspeed’s overall strategy for China. In 2006, he moved himself and his family to Shanghai for five months to help formally establish Lightspeed’s China office, build the local investment team, and make several of the firm’s initial investments in the region, one of which became the firm’s first successful liquidity event in China.

Prior to Lightspeed, Eric was an Associate at InterWest Partners, a Silicon Valley venture capital firm where he focused on communications, internet and consumer investments. He has also worked for and consulted to a number of technology startups, and started his career as an Analyst in the mergers and acquisitions and corporate finance groups at Morgan Stanley in New York and San Francisco. Eric holds an AB degree in Economics magna cum laude from Harvard College and an MBA from the Stanford Graduate School of Business.

Eric O'Brien, MBA

Co-Founder & Managing Director of Fall Line Capital

Dr. Ganesh Kishore is an entrepreneur and has co-founded three successful entities since 2002.  Two of the three entities are now parts of publicly traded entities (Tata/Rallis in India and Evolva in Switzerland) while the third business entity (Mogene LC in USA) serves both as an incubator of new ideas as well as a provider of genomic services across agriculture, health care and environment.  He serves on the board of three publicly listed entities, three privately held companies and the Advisory Board of Washington University.  He is also an advisor to multinational companies and Scientific American. Dr. Kishore has a distinguished track record of accomplishments in biotechnology research and development and business.  He left DuPont in 2007 where he was Chief Biotechnology Officer to join Malaysian Life Science Capital Fund (MLSCF) as its CEO and later co-founded Spruce Capital Partners in 2013. After receiving a Ph.D. in biochemistry from Indian Institute of Science, Dr. Kishore received postdoctoral training in chemistry and biology and also served as a Robert A Welch Fellow at The University of Texas at Austin. He then joined Monsanto Company as a Senior Research Biochemist, responsible for developing processes for the synthesis of Aspartame, the active ingredient of Nutrasweet and Equal.  He subsequently took leadership for discovering and developing the Roundup Ready technology and ultimately the entire agricultural technologies and biotechnology for Monsanto.  He was named a Distinguished Science Fellow, the highest honor bestowed upon scientists who have made outstanding contributions to the company but also the scientific field in general, and Assistant Chief Scientist of the company. In 2002, Dr. Kishore joined DuPont as the Chief Technology Officer for its Agriculture and Nutrition Platform and took over the role of Chief Biotechnology Officer for the company in 2005.  During his tenure at DuPont, he guided the acquisition of several key technology companies and relationships and bolstered the biotech competence within the company.

Dr. Ganesh Kishore is an entrepreneur and has co-founded three successful entities since 2002.  Two of the three entities are now parts of publicly traded entities (Tata/Rallis in India and Evolva in Switzerland) while the third business entity (Mogene LC in USA) serves both as an incubator of new ideas as well as a provider of genomic services across agriculture, health care and environment.  He serves on the board of three publicly listed entities, three privately held companies and the Advisory Board of Washington University.  He is also an advisor to multinational companies and Scientific American.

Dr. Kishore has a distinguished track record of accomplishments in biotechnology research and development and business.  He left DuPont in 2007 where he was Chief Biotechnology Officer to join Malaysian Life Science Capital Fund (MLSCF) as its CEO and later co-founded Spruce Capital Partners in 2013.

After receiving a Ph.D. in biochemistry from Indian Institute of Science, Dr. Kishore received postdoctoral training in chemistry and biology and also served as a Robert A Welch Fellow at The University of Texas at Austin. He then joined Monsanto Company as a Senior Research Biochemist, responsible for developing processes for the synthesis of Aspartame, the active ingredient of Nutrasweet and Equal.  He subsequently took leadership for discovering and developing the Roundup Ready technology and ultimately the entire agricultural technologies and biotechnology for Monsanto.  He was named a Distinguished Science Fellow, the highest honor bestowed upon scientists who have made outstanding contributions to the company but also the scientific field in general, and Assistant Chief Scientist of the company.

In 2002, Dr. Kishore joined DuPont as the Chief Technology Officer for its Agriculture and Nutrition Platform and took over the role of Chief Biotechnology Officer for the company in 2005.  During his tenure at DuPont, he guided the acquisition of several key technology companies and relationships and bolstered the biotech competence within the company.

Ganesh Kishore, Ph.d.

CEO, Malaysian Life Sciences Capital Fund and Managing Partners, Spruce Capital Partners


INVESTORS